Literature DB >> 15492825

Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas.

Anita Olofsson1, Helena Willén, Melker Göransson, Katarina Engström, Jeanne M Meis-Kindblom, Göran Stenman, Lars-Gunnar Kindblom, Pierre Aman.   

Abstract

Myxoid/round cell liposarcomas (MLS/RCLS) are characterized by chromosome translocations that result in formation of FUS-CHOP or EWSR1-CHOP fusion oncogenes. More than 95% of the tumors carry one of these fusion genes. FUS-CHOP transforms 3T3 cells and causes MLS/RCLS-like tumors in transgenic mice. The fusion oncoproteins act as abnormal transcription factors and are believed to induce abnormal expression of growth controlling genes as part of their transforming activities. The aim of this study was to search for recurrent abnormal expression patterns of cell cycle regulating proteins and growth factor receptors. A series of 14 MLS/RCLS, 2 MLS/RCLS derived cell lines and a FUS-CHOP transfected human sarcoma cell line were analyzed using immunohistochemistry, Western blotting, and cDNA microarray based screening. The results revealed a highly abnormal expression pattern of several growth controlling proteins. The G1 cyclins D1 and E and their associated kinases CDK4 and CDK2 were strongly overexpressed in all of the tumors. High expression levels were also found for Cdk4/6 inhibitor P16 and CDK2 inhibitors P27 and P57. The growth factor tyrosine kinase receptors PDGFRB and EGFR were present in most cells of all investigated tumors. We conclude that deregulation of G1 controlling proteins is common in MLS/RCLS and that aberrant expression of these proteins is of importance in the pathogenesis of this tumor type.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492825

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles.

Authors:  Dingfeng Jiang; Naiqing Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-08       Impact factor: 4.553

2.  Genome wide array analysis indicates that an amyotrophic lateral sclerosis mutation of FUS causes an early increase of CAMK2N2 in vitro.

Authors:  Paolo Convertini; Jiayu Zhang; Pierre de la Grange; Lawrence J Hayward; Haining Zhu; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2013-03-29

3.  Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.

Authors:  Mattias K Andersson; Melker Göransson; Anita Olofsson; Carola Andersson; Pierre Aman
Journal:  BMC Cancer       Date:  2010-06-01       Impact factor: 4.430

Review 4.  [Identification of genes over-expressed in myxoid/round cell liposarcoma. DNA microarray analysis and immunohistochemical correlation].

Authors:  C Lanckohr; A Kasprzynski; L Klein-Hitpass; H-H Homann; M Lehnhardt; O Müller; C Kuhnen; P Herter
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

5.  Myxoid Liposarcoma: Prognostic Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single Institution.

Authors:  Francesco Muratori; Leonardo Bettini; Filippo Frenos; Nicola Mondanelli; Daniela Greto; Lorenzo Livi; Alessandro Franchi; Giuliana Roselli; Maurizio Scorianz; Rodolfo Capanna; Domenico Campanacci
Journal:  Int J Surg Oncol       Date:  2018-05-16

Review 6.  CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets.

Authors:  Jordan L Kohlmeyer; David J Gordon; Munir R Tanas; Varun Monga; Rebecca D Dodd; Dawn E Quelle
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

7.  DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.

Authors:  Christoffer Bento; Mattias K Andersson; Pierre Aman
Journal:  BMC Cell Biol       Date:  2009-12-17       Impact factor: 4.241

8.  Cell senescence in myxoid/round cell liposarcoma.

Authors:  Christina Kåbjörn Gustafsson; Anders Ståhlberg; Katarina Engtröm; Anna Danielsson; Ingela Turesson; Pierre Aman
Journal:  Sarcoma       Date:  2014-06-24

9.  HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Authors:  Setareh Safavi; Sofia Järnum; Christoffer Vannas; Sameer Udhane; Emma Jonasson; Tajana Tesan Tomic; Pernilla Grundevik; Henrik Fagman; Magnus Hansson; Zeynep Kalender; Alexandra Jauhiainen; Soheila Dolatabadi; Eva Wessel Stratford; Ola Myklebost; Mikael Eriksson; Göran Stenman; Regine Schneider-Stock; Anders Ståhlberg; Pierre Åman
Journal:  Oncotarget       Date:  2016-01-05

10.  HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.

Authors:  Michaela Angelika Ihle; Sabine Merkelbach-Bruse; Wolfgang Hartmann; Sebastian Bauer; Nancy Ratner; Hiroshi Sonobe; Jun Nishio; Olle Larsson; Pierre Åman; Florence Pedeutour; Takahiro Taguchi; Eva Wardelmann; Reinhard Buettner; Hans-Ulrich Schildhaus
Journal:  J Pathol Clin Res       Date:  2016-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.